Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aptiv Solutions Launches ADDPLAN® DF

Published: Monday, September 23, 2013
Last Updated: Sunday, September 22, 2013
Bookmark and Share
An innovative software for optimizing dose selection in phase 2 trials.

Aptiv Solutions has announced the release of ADDPLAN® DF, an innovative software that designs, simulates, and analyzes Phase 2 dose finding studies to make them more efficient and effective.

ADDPLAN® DF is the latest product in the ADDPLAN® family that includes a series of products for adaptive confirmatory trials.

ADDPLAN® DF is a fully-validated design and analysis tool based on MCP-Mod methodology (a combination of Multiple Comparison Procedures and Modeling) and covers dose finding designs for establishing Proof of Concept and determining the optimum target dose to select for Phase 3 trials.

This tool will enable drug developers to remove a number of the uncertainties inherent in Phase 2 dose finding trials and improve critical decisions on dose-selection, which will directly impact the probability of success in Phase 3.

Currently half of Phase 3 trials fail, in part because of poor dose selection in Phase 2. Regulators, pharmaceutical companies and industry groups recognize that more robust Phase 2 studies are required to improve dose selection and this is the stimulus driving the development of ADDPLAN® DF.

“The consequences of improving dose selection should be measured in terms of the success rates of subsequent Phase 3 trials,” says Professor Andy Grieve, Senior Vice President, Clinical Trial Methodology for Aptiv Solutions and co-author, with Tobias Mielke and Parvin Fardipour, of a new white paper on the critical importance of dose finding trials.

Professor Grieve continued, “The business value of improving dose selection can amount to billions of dollars across a product portfolio and importantly deliver an increased number of novel medicines to patients.”

There has been a recent increase in the adoption of innovative designs in exploratory phase trials stimulated by vocal support from the FDA and EMA. “Getting it right at Phase 2” has been a rallying call from both regulators and industry for some time and the availability of ADDPLAN® DF will significantly help to achieve this objective.

In July, ADDPLAN® DF was pre-released in beta version to a top 5 pharma company that served as the prime development partner for the software. Two additional large pharma customers have also received the software as founding members of the ADDPLAN® DF Consortium announced earlier this year. The software will be available for purchase by other interested stakeholders in mid-October.

“Among the many advantages we see with ADDPLAN® DF,” says Professor Grieve, “is its adaptive analysis and modeling capability. Using the design engine, the optimal allocation rates for a robust dose-estimation can be calculated. The simulation engine allows the verification of characteristics of the chosen design, and the analysis engine enables data analysis using different multiple comparison procedures, modeling approaches and the combined MCP-Mod approach. This creates the optimum method to select the dose for confirmatory Phase 3 studies.”

The benefits of ADDPLAN® DF are applicable to mid-size and large pharmaceutical companies taking novel products through Phase 3, as well as biotech companies looking to increase the value of their early stage assets and to partner at Phase 2.

A further application is in medical device development where different strengths of a specific stimulus need to be evaluated.

This release of ADDPLAN® DF is the first in a series of novel methodologies for use in Phase 2 clinical trials. Subsequent versions will be released that deliver additional benefits to this critical phase of exploratory development.

The white paper titled ‘ADDPLAN® DF - An Advanced Tool for Optimizing Dose Selection in Exploratory Drug Development’ is available at http://www.aptivsolutions.com/addplan-df-landing-page/.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aptiv Solutions to be Acquired by ICON
Combined companies provide unrivalled capabilities for adaptive and medical device trials worldwide.
Monday, March 31, 2014
Tufts CSDD Study Finds Adoption of Adaptive Clinical Trial Designs is Increasing
Report shows growing acceptance by pharmaceutical companies and regulatory agencies.
Friday, May 24, 2013
Aptiv Solutions Growing: Opens New Office in North Carolina
New office is located at 4505 Emperor Boulevard in the Imperial Center.
Monday, December 10, 2012
Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!